Anti-inflammatory treatments for stroke: from bench to bedside

被引:63
|
作者
Drieu, Antoine [1 ]
Levard, Damien [1 ]
Vivien, Denis [1 ,2 ]
Rubio, Marina [1 ]
机构
[1] Normandy Univ, Pathophysiol & Imaging Neurol Disorders, Blvd Henri Becquerel BP 5229, F-14000 Caen, France
[2] CHU Caen, Imaging Neurol Disorders, Caen, France
关键词
clinical trial; immunomodulatory drugs; inflammation; stroke models; translation; ACUTE ISCHEMIC-STROKE; REGULATORY T-CELLS; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; INTERLEUKIN-1 RECEPTOR ANTAGONIST; IMMUNE MODULATOR FINGOLIMOD; SENSITIVE MOLECULAR MRI; CENTRAL-NERVOUS-SYSTEM; REDUCES BRAIN-DAMAGE; THROMBOEMBOLIC STROKE;
D O I
10.1177/1756286418789854
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Sex or gender? - Insights into stroke from community, bedside and bench
    Srikanth, Velandai
    [J]. AUSTRALASIAN JOURNAL ON AGEING, 2016, 35 : 13 - 13
  • [32] Bench to Bedside: Discussion of Past and Future Treatments
    Melamed, E.
    [J]. MOVEMENT DISORDERS, 2010, 25 : S585 - S586
  • [33] Anti-leukotrienes as novel anti-inflammatory treatments in asthma
    Drazen, JM
    [J]. EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY, 5, 2002, 507 : 217 - 221
  • [34] Inflammatory mediators of cytokines and chemokines in sepsis: From bench to bedside
    Doganyigit, Zuleyha
    Eroglu, Ece
    Akyuz, Enes
    [J]. HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [35] From bench to bedside: molecular imaging in inflammatory bowel diseases
    Atreya, Raja
    Neurath, Markus F.
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2016, 32 (04) : 245 - 250
  • [36] Immune and Inflammatory-Mediated Disorders: From Bench to Bedside
    Reale, Marcella
    Conti, Lucia
    Velluto, Diana
    [J]. JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [37] New therapies for inflammatory bowel disease: from the bench to the bedside
    Danese, Silvio
    [J]. GUT, 2012, 61 (06) : 918 - 932
  • [38] Inflammatory mediators of cytokines and chemokines in sepsis: From bench to bedside
    Doganyigit, Zuleyha
    Eroglu, Ece
    Akyuz, Enes
    [J]. HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [39] Anti-Inflammatory Small Molecules To Treat Seizures anc Eoileosy: From Bench to Becsice
    Dey, Avijit
    Kang, Xu
    Qiu, Jiange
    Du, Yifeng
    Jiang, Jianxiong
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (06) : 463 - 484
  • [40] From bench to bedside
    Alberti, A
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (03) : 301 - 301